Compare ULH & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULH | ZURA |
|---|---|---|
| Founded | 1932 | 2022 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Trucking Freight/Courier Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.3M | 455.4M |
| IPO Year | 2004 | N/A |
| Metric | ULH | ZURA |
|---|---|---|
| Price | $14.35 | $5.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $20.00 | $13.00 |
| AVG Volume (30 Days) | 43.1K | ★ 1.7M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,461,708,000.00 | N/A |
| Revenue This Year | $2.73 | N/A |
| Revenue Next Year | $5.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.73 | $1.35 |
| 52 Week High | $30.76 | $7.25 |
| Indicator | ULH | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 45.52 | 58.59 |
| Support Level | $13.05 | $5.28 |
| Resistance Level | $18.76 | $5.88 |
| Average True Range (ATR) | 0.94 | 0.49 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 43.71 | 50.86 |
Universal Logistics Holdings Inc is an asset-light provider of customized transportation and logistics solutions throughout the United States, and in Mexico, Canada, and Colombia. It offers services such as truckload, brokerage, intermodal, dedicated, and value-added services. The firm has three reportable segments, namely contract logistics, intermodal, and trucking. The company generates the key revenue from Contract Logistics, which provides value-added and dedicated transportation services to support inbound and internal logistics requirements of industrial manufacturers and retailers, generally under contractual arrangements of one year or longer. Geographically, the firm generates the majority of its revenue from the United States, followed by Mexico, Canada, and Colombia.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.